US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by PepGen, Inc
PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates
November 14, 2022
From
PepGen, Inc
Via
GlobeNewswire
Tickers
PEPG
PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
November 10, 2022
From
PepGen, Inc
Via
GlobeNewswire
Tickers
PEPG
PepGen to Participate in the Stifel 2022 Healthcare Conference
November 08, 2022
From
PepGen, Inc
Via
GlobeNewswire
Tickers
PEPG
PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress
October 13, 2022
From
PepGen, Inc
Via
GlobeNewswire
Tickers
PEPG
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
September 28, 2022
From
PepGen, Inc
Via
GlobeNewswire
Tickers
PEPG
